Finder Award
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
ZIOPHARM Oncology is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a trailing 12-month revenue of around $398,000.
How to buy ZIOPHARM Oncology stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ZIOP. It's that simple.
Finder Award
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
ZIOPHARM Oncology stock price (NASDAQ: ZIOP)
Use our graph to track the performance of ZIOP stocks over time.ZIOPHARM Oncology shares at a glance
Information last updated 2022-03-20.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $1.07 |
| 200-day moving average | $1.89 |
| Wall St. target price | $3.92 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.42 |
Buy ZIOPHARM Oncology stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.1 - 5 of 5
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy ZIOPHARM Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ZIOPHARM Oncology price performance over time
Historical closes compared with the close of $0 from 2022-02-14
| 1 week (2023-01-16) | nan% |
|---|---|
| 1 month (2022-12-23) | nan% |
| 3 months (2022-10-23) | nan% |
| 6 months (2022-07-23) | nan% |
| 1 year (2022-01-26) | -100.00% |
|---|---|
| 2 years (2021-01-27) | -100.00% |
| 3 years (2020-01-27) | 4.3 |
| 5 years (2018-01-26) | 4.61 |
ZIOPHARM Oncology financials
| Revenue TTM | $398,000 |
|---|---|
| Gross profit TTM | $-52,696,000 |
| Return on assets TTM | -39.32% |
| Return on equity TTM | -84.01% |
| Profit margin | 0% |
| Book value | $0.32 |
| Market capitalisation | $187.1 million |
TTM: trailing 12 months
ZIOPHARM Oncology share dividends
We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.
Have ZIOPHARM Oncology's shares ever split?
ZIOPHARM Oncology's shares were split on a 1:40 basis on 24 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.
ZIOPHARM Oncology share price volatility
Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 1.6868. This would suggest that ZIOPHARM Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ZIOPHARM Oncology overview
ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.
Frequently asked questions
What percentage of ZIOPHARM Oncology is owned by insiders or institutions?Currently 9.927% of ZIOPHARM Oncology shares are held by insiders and 56.28% by institutions. How many people work for ZIOPHARM Oncology?
Latest data suggests 103 work at ZIOPHARM Oncology. When does the fiscal year end for ZIOPHARM Oncology?
ZIOPHARM Oncology's fiscal year ends in December. Where is ZIOPHARM Oncology based?
ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129 What is ZIOPHARM Oncology's ISIN number?
ZIOPHARM Oncology's international securities identification number is: US98973P1012 What is ZIOPHARM Oncology's CUSIP number?
ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101
More guides on Finder
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
-
Best international stock brokers for 2023
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
Ask an Expert